文献速递白血病造血干细胞移植与细胞治疗

单倍体mbIL-21体外扩增NK细胞治疗多次复发难治性急性髓系白血病的I期试验结果

Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
PubMed 文献 · Am J Hematol · 2024-03-05

一项I期临床试验用氟达拉滨/阿糖胞苷后输注6次单倍体供者来源的mbIL-21体外扩增NK细胞治疗12例难治性急性髓系白血病患者(中位年龄60岁,中位既往治疗线数5线,中位骨髓原始细胞47%),未观察到毒性或移植物抗宿主病,未达到最大耐受剂量;7例(58.3%)达完全缓解(伴或不伴计数恢复),中位最佳缓解时间48天,中位随访52个月时全组1年总生存率41.7%。

要点

  • 12例难治性AML患者接受单倍体mbIL-21体外扩增NK细胞输注,未观察到毒性或GVHD,未达到MTD。
  • 7例(58.3%)达CR/CRi,中位最佳缓解时间48天,5例缓解后接受同一供者单倍体移植。
  • 中位随访52个月,全组1年OS 41.7%,CR/CRi缓解者57.14%,缓解后移植者60%。

核心结论

  • 在难治性AML患者中观察到对体外扩增NK细胞给药的显著缓解且无不良反应。

研究设计与样本

  • I期临床试验,纳入12例难治性急性髓系白血病患者,中位年龄60岁,中位既往治疗线数5线,中位骨髓原始细胞计数47%。
  • 患者接受氟达拉滨/阿糖胞苷后输注6次单倍体供者来源、经表达膜结合IL21和4-1BBL的K562饲养细胞扩增的NK细胞,剂量为106-107/kg/次。

主要发现

  • 未观察到毒性或移植物抗宿主病,未达到最大耐受剂量。
  • 7例(58.3%)达完全缓解(伴或不伴计数恢复),中位最佳缓解时间48天。
  • 5例缓解患者接受同一供者单倍体移植。
  • 中位随访52个月,全组1年总生存率41.7%,CR/CRi缓解者为57.14%,缓解后移植者为60%。
  • 患者血液中可检测到供者来源NK细胞的持续存在与扩增,血清IFNγ水平随NK细胞输注同步升高;计数-功能抑制性KIR较高与达CR/CRi可能性较高相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Natural killer (NK)-cells have potent anti-tumor effects, yet it remains unclear if they are effective for patients with relapsed acute myeloid leukemia (AML). In a phase I clinical trial, we treated 12 patients (median age 60 years) with refractory AML (median 5 lines of prior therapy, median bone marrow blast count of 47%) with fludarabine/cytarabine followed by 6 infusions of NK-cells expanded from haploidentical donors using K562 feeder cells expressing membrane-bound IL21 and 4-1BBL. Patients received 106-107/kg/dose. No toxicity or graft-versus-host disease (GVHD) was observed and MTD was not reached. Seven patients (58.3%) responded and achieved a complete remission (CR) with/without count recovery. Median time to best response was 48 days. Five responding patients proceeded to a haploidentical transplant from the same donor. After a median follow-up of 52 months, 1-year overall survival (OS) for the entire group was 41.7%, better for patients who responded with CR/CRi (57.14%), and for patients who responded and underwent transplantation (60%). Persistence and expansion of donor-derived NK-cells were identified in patients' blood, and serum IFNγ levels rose concurrently with NK cell infusions. A higher count-functional inhibitory KIR was associated with higher likelihood of achieving CR/CRi. In conclusion, we observed a significant response to ex vivo expanded NK-cell administration in refractory AML patients without adverse effects.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ciurea SO, Kongtim P, Srour S, et al. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024. PMID: 38444268. doi:10.1002/ajh.27281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。